Ovarian Cancer
Conditions
Brief summary
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.
Interventions
DRUGSHR-A1811
SHR-A1811.
DRUGCarboplatin
Carboplatin.
DRUGBevacizumab
Bevacizumab.
Oxaliplatin for injection.
DRUGPaclitaxel injection
Paclitaxel injection.
Doxorubicin hydrochloride liposome injetction.
Adebrelimab injection.
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with the follow-up. 2. Sufficient fresh or archived tumor tissue specimens can be provided for testing by the third-party central laboratory designated by the sponsor. 3. At least one measurable lesion conforming to RECIST v1.1. 4. ECOG PS score: 0-1. 5. Expected survival ≥ 12 weeks. 6. Female subjects with fertility must agree to comply with the contraceptive requirements from signing the informed consent form to 7 months after the last administration of the trial drug.
Exclusion criteria
1. With untreated or active central nervous system (CNS) tumor metastasis. Subjects with a history of meningeal metastasis or current meningeal metastasis. 2. Pleural effusion, pericardial effusion or peritoneal effusion with clinical symptoms, which cannot be well controlled. 3. Previous interstitial pneumonia or interstitial lung disease, non infectious pneumonia requiring steroid treatment. 4. With hypertension and cannot be well controlled by antihypertensive drug treatment. 5. Accompanied by poorly controlled or serious cardiovascular diseases. 6. Subjects with serious infection within 1 month before the first medication. 7. Have a history of immune deficiency, including HIV test positive, other acquired or congenital immune deficiency diseases, or a history of organ transplantation. 8. There are any other factors that may affect the results of the study or cause the forced termination of the study, such as alcohol abuse, drug abuse, criminal detention, and other serious diseases (including mental illness) that need combined treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose limited toxicity (DLT) | Up to 21 days. |
| Recommended phase II dose (RP2D) | Up to 21 days. |
| Objective response rate (ORR) | Every 9 weeks lasting about one year. |
Secondary
| Measure | Time frame |
|---|---|
| Standard response rate (RR) | Every 9 weeks lasting about one year. |
| Overall survival (OS) | Approximately 3 years after the last subject enrolled. |
| Duration of response (DoR) | Every 9 weeks lasting about one year. |
| Serious adverse events (SAEs) | From the first drug administration to within 90 days after the last dose. |
| Adverse events (AEs) | From the first drug administration to within 90 days after the last dose. |
| Disease control rate (DCR) | Every 9 weeks lasting about one year. |
| Progression free survival (PFS) | Every 9 weeks lasting about one year. |
Countries
China
Contacts
Primary ContactShuni Wang
Outcome results
None listed